(Reuters) -British stocks closed lower on Wednesday as losses in healthcare and real estate shares offset positive trade talk ...

Britain's main indexes fell on Wednesday, with healthcare and real estate stocks leading the decline despite positive trade ...

Vivo Capital ("Vivo" or "the Firm"), a leading global investment firm focused exclusively on healthcare and life sciences, ...

DelveInsight’s Renal Cell Carcinoma Pipeline report depicts a robust space with 30+ active players working to develop 30+ ...

Novo Nordisk will halt gender representation goals in its U.S. operations to comply with recent executive orders by President Trump against diversity initiatives, diverging from its global commitment ...

The AstraZeneca share price has pulled back in recent months. Dr James Fox explores how the stock compares with pharma peer GSK. The post Does the GSK or AstraZeneca share price currently offer the ...

Afatinib has broad activity against EGFR mutations. However, the approval for uncommon mutations was based on data from 38 ...

Shares of GSK PLC GSK slid 4.90% to £13.79 Wednesday, on what proved to be an all-around rough trading session for the stock ...

Shares in GSK and AstraZeneca came under pressure on Wednesday, after vaccine-sceptic Vinay Prasad was appointed to a key ...

Learn about April 2025’s top biotech deals, featuring major collaborations in bispecific antibodies, protein therapies, and ...

The ASX has dipped this morning, tracking down 0.23pc. The ASX Gold and Tech indices are on the rise, despite a fall in gold prices overnight.

Britain's main indexes saw a downturn on Wednesday, driven by declines in healthcare and real estate stocks, even as progress ...